热景生物股价跌5.06%，万家基金旗下1只基金重仓，持有11.53万股浮亏损失143.56万元

Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.06% in its stock price, reaching 233.38 yuan per share, with a trading volume of 2.23 billion yuan and a turnover rate of 1.00%, resulting in a total market capitalization of 216.36 billion yuan [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, is primarily engaged in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: diagnostic reagents 81.20%, diagnostic instruments 15.52%, biological raw materials 2.13%, and others 1.15% [1] Group 2 - From the perspective of fund holdings, 万家基金 (Wanjia Fund) has one fund heavily invested in Hotgen Biotech. The 万家新机遇成长一年持有期混合发起式A (Wanjia New Opportunities Growth One-Year Holding Mixed Fund A) held 115,300 shares in the second quarter, accounting for 2.25% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 1.4356 million yuan [2] - The 万家新机遇成长一年持有期混合发起式A fund was established on December 7, 2021, with a current scale of 579 million yuan. Year-to-date returns are 19.07%, ranking 3976 out of 8194 in its category; the one-year return is 12.44%, ranking 6446 out of 7962; and since inception, it has incurred a loss of 2.49% [2]